4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hot and cold tumors: Immunological features and the therapeutic strategies

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The “hotness” or “coldness” of the tumors are determined by the information of the cancer cells themselves, tumor immune characteristics, tumor microenvironment, and signaling mechanisms, which are key factors affecting cancer patients’ clinical efficacy. The switch mechanism of “hotness” and “coldness” and its corresponding pathological characteristics and treatment strategies are the frontier and hot spot of tumor treatment. How to distinguish the “hotness” or “coldness” effectively and clarify the causes, microenvironment state, and characteristics are very important for the tumor response and efficacy treatments. Starting from the concept of hot and cold tumor, this review systematically summarized the molecular characteristics, influencing factors, and therapeutic strategies of “hot and cold tumors,” and analyzed the immunophenotypes, the tumor microenvironment, the signaling pathways, and the molecular markers that contribute to “hot and cold tumors” in details. Different therapeutic strategies for “cold and hot tumors” based on clinical efficacy were analyzed with drug targets and proteins for “cold and hot tumors.” Furthermore, this review combines the therapeutic strategies of different “hot and cold tumors” with traditional medicine and modern medicine, to provide a basis and guidance for clinical decision‐making of cancer treatment.

          Abstract

          The characteristics of coldness and hotness tumors are determined by the information of cancer cells and tumor microenvironments, which significantly affects cancer patients’ clinical efficacy. Different therapeutic strategies for cold and hot tumors based on clinical efficacy were analyzed through clinical drug targets, tumor microenvironments, and tumor stages. Coldness tumors can transform into hotness tumors through chemotherapy, radiotherapy, targeted therapy, and other therapies.

          Related collections

          Most cited references257

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The blockade of immune checkpoints in cancer immunotherapy.

            Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

              Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade.
                Bookmark

                Author and article information

                Contributors
                sliang621@163.com
                bw0999@hotmail.com
                zlhtcm@hotmail.com
                Journal
                MedComm (2020)
                MedComm (2020)
                10.1002/(ISSN)2688-2663
                MCO2
                MedComm
                John Wiley and Sons Inc. (Hoboken )
                2688-2663
                26 August 2023
                October 2023
                : 4
                : 5 ( doiID: 10.1002/mco2.v4.5 )
                : e343
                Affiliations
                [ 1 ] Department of Medical Oncology and Cancer Institute Shuguang Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
                [ 2 ] Department of Internal Medicine Shanghai International Medical Center Shanghai China
                [ 3 ] Department of Nephrology Shuguang Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
                [ 4 ] Department of the Tumor Research Center, Academy of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
                [ 5 ] Department of Medical Oncology Ningbo Hospital of Traditional Chinese Medicine, Zhejiang Province Ningbo China
                Author notes
                [*] [* ] Correspondence

                Lihong Zhou, Department of Medical Oncology and Cancer Institute of Integrative, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

                Email: zlhtcm@ 123456hotmail.com

                Yan Wang, Department of Medical Oncology and Cancer Institute of Integrative, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

                Email: bw0999@ 123456hotmail.com

                Shiliang Ling, Department of Medical Oncology, Ningbo Hospital of Traditional Chinese Medicine, Ningbo 315010, China.

                Email: sliang621@ 123456163.com

                [#]

                Lianjie Wang, Hui Geng, Yujie Liu contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-1771-5902
                Article
                MCO2343
                10.1002/mco2.343
                10458686
                37638340
                7c53051b-a2d3-432c-9312-a8b0113dc84f
                © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 July 2023
                : 13 January 2023
                : 18 July 2023
                Page count
                Figures: 7, Tables: 1, Pages: 21, Words: 14050
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 82174145
                Award ID: 82030118
                Award ID: 81973651
                Funded by: General Program, Shanghai Frontier Research Base for Translational Disease Biology of Inflammatory Cancer
                Award ID: 2021KJ03‐12
                Funded by: Shanghai three‐year action plan for the development of traditional Chinese medicine
                Award ID: ZY(2021‐2023)−0208
                Categories
                Review
                Reviews
                Custom metadata
                2.0
                October 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.3 mode:remove_FC converted:26.08.2023

                cancer,hotness and coldness of tumors,immune characteristics,signaling mechanism,therapeutic strategies,tumor microenvironment

                Comments

                Comment on this article